Table 1.
Baseline Characteristics
| Characteristics | Advanced Therapies or Death (n = 150) | Medical Management (n = 74) | P Value |
|---|---|---|---|
| Age, years | 57(48–66) | 58 (47–64) | .56 |
| Female | 101 (67.3) | 48 (64.9) | .71 |
| Race | .56 | ||
| Caucasian or White | 63 (42.0) | 25 (33.8) | |
| African American or Black | 76 (50.7) | 43 (58.1) | |
| Asian | 2(1.3) | 2(2.7) | |
| Other | 9(6.0) | 4(5.4) | |
| Nonischemic cardiomyopathy | 108 (72.0) | 46 (62.2) | .14 |
| Coronary artery disease | 57(38.0) | 31 (41.9) | .58 |
| Hypertension | 68 (45.3) | 44 (59.5) | .05 |
| Hyperlipidemia | 38 (25.3) | 21 (28.4) | .63 |
| Atrial fibrillation | 59(39.3) | 30 (40.5) | .86 |
| Diabetes mellitus | 60 (40.0) | 25 (33.8) | .37 |
| Chronic obstructive pulmonary disease | 14(9.3) | 5 (6.8) | .52 |
| Stroke | 13(8.7) | 15 (20.3) | .93 |
| Chronic kidney disease | 66 (44.0) | 33 (44.6) | .89 |
| ACE-I | 50(33.3) | 24(32.4) | .85 |
| ARB | 30 (20.0) | 14(18.9) | .46 |
| ARNI | 26(17.3) | 10(13.5) | .38 |
| ACE-I, ARB, or ARNI | 106 (70.7) | 48(64.9) | .87 |
| Beta-blocker | 123(82.0) | 60(81.1) | .16 |
| Aldosterone antagonist | 95 (63.8) | 40(54.1) | .85 |
| Hydralazine | 15(10.0) | 8(10.8) | .34 |
| Isosorbide dinitrate | 9 (6.0) | 7 (9.5) | .34 |
| Digoxin | 37 (24.7) | 14(18.9) | .93 |
| Left ventricular ejection fraction, % | 20.1 (15.2–26.0) | 21.7(17.1–30.6) | .07 |
| Creatinine, mg/dL | 1.3(1.1–1.6) | 1.4(1.1–1.8) | .18 |
| Estimated glomerular filtration rate, mL/min/1.73 m2 | 55(38–70) | 47(32–68) | .17 |
| Moderate Sedation during Procedure | 74 (49.3) | 29 (39.2) | .15 |
Values are median (IQR) or number (%). ACE-I, angiotensin-converting enzyme inhibitor, ARB, angiotensin receptor blocker, ARNI, angiotensin receptor neprolysin inhibitor, IQR, interquartile range.